DisperSol signs up Catalent for manufacturing of multiple pharma products

The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, and CDMO Catalent have struck a strategic manufacturing collaboration to advance and accelerate the development of multiple DisperSol pharmaceutical products.

The collaboration will see the installation of a commercial-scale KinetiSol technology manufacturing line at Catalent’s oral solids development and manufacturing facility in Somerset, New Jersey, where, according to Jeremie Trochu, Catalent's Vice President, Operations, Early Phase Development, it has a "track record of introducing and industrialising new oral technologies,"

DisperSol's proprietary KinetiSol technology helps to overcome drug solubility or manufacturing limitation issues to create novel oral therapeutics.

The technology underlies all of DisperSol’s pipeline programs including Phase III ready KDFX for iron overload disorder, and KABE, which recently started Phase II studies against prostate cancer.

As part of the agreement, DisperSol will tech transfer its proprietary equipment, software and expertise to a dedicated suite in Catalent’s Somerset facility.

Catalent will provide staff for development, scale up, and commercial-stage KinetiSol production, as well as associated capabilities including process engineering, quality control and assurance.